PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization
about
Is There Still Room for Cancer Vaccines at the Era of Checkpoint InhibitorsImmunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer.Inducible expression of cancer-testis antigens in human prostate cancer.B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccinesProspective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines.Immunotherapy in prostate cancer: challenges and opportunities.Clinical development of immunotherapy for prostate cancer.Immunotherapy for prostate cancer: False promises or true hope?Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8+ T cells and inferior antitumor responses.5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.Antitumor vaccination of prostate cancer patients elicits PD-1/PD-L1 regulated antigen-specific immune responses.TCR diversity - a universal cancer immunotherapy biomarker?Beyond the androgen receptor II: New approaches to understanding and treating metastatic prostate cancer; Report from the 2017 Coffey-Holden Prostate Cancer Academy Meeting.Therapeutic Cancer Vaccines: How Much Closer Are We?Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT.Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells.Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.DNA vaccines for prostate cancer.Combination Immunotherapy: Taking Cancer Vaccines to the Next Level.Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer.Trial watch: DNA-based vaccines for oncological indications
P2860
Q28072532-5906E28F-068F-4D59-89D4-0239B8FDC330Q36936564-D9C7F0DF-F3AD-4915-A921-16168794DAC0Q37686238-6C256557-1DEF-4170-8BE2-0966B780708EQ37708724-B6CBC8AE-7738-43C6-A9EB-61F9BF31981DQ38643567-A5318D48-F349-4FE5-A629-34E7E4666625Q38661079-B5BD46FC-71B8-4D78-B9CA-16DCA8F30C1CQ38668561-2CEA8F72-B1F4-489C-9E1B-5FD951AF79E7Q38959645-AD4558D6-6006-4458-B2D1-AE00EB91E701Q39181825-23B17213-CF2E-4CAB-8ED2-B6A5D5846D69Q40188258-457FF6FB-5D18-4FA5-AA24-2BFDCEB79111Q40517920-B74F5633-236C-4781-B301-948EF1454994Q41869616-876ADA7F-1C61-45B2-8DE2-4C3284A563D5Q42368649-FD703C7C-4089-4EF8-914F-CE529101D1ACQ43578455-5B6B0E3B-BA72-4A30-BCCA-F89EE2618BE1Q47235984-376EB3DE-82F4-495F-84FC-91956A603FAAQ49715023-1135FF1B-AB9F-4FB4-A34D-058F3699C639Q50222492-E60C8FC6-6B24-4B6F-8D15-2C9E2504B63FQ50266733-41C9AD34-2BD3-4D17-9FBB-FF0CD4FFB8AFQ51142505-C23A9D16-289D-4D74-97CD-28E628F2B948Q52603627-0BD414F7-8BF7-49E5-8A64-967E6FE1E050Q55263045-39EBD9CD-9289-4A00-81C8-8AB62227AF90Q56893452-C59D021F-8511-4588-AE1E-4E8AE42F9AA3
P2860
PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
PD-1 or PD-L1 Blockade Restore ...... ified DNA Vaccine Immunization
@en
type
label
PD-1 or PD-L1 Blockade Restore ...... ified DNA Vaccine Immunization
@en
prefLabel
PD-1 or PD-L1 Blockade Restore ...... ified DNA Vaccine Immunization
@en
P2093
P2860
P1476
PD-1 or PD-L1 Blockade Restore ...... ified DNA Vaccine Immunization
@en
P2093
Brett B Maricque
Brian M Olson
Brian T Rekoske
Douglas G McNeel
Heath A Smith
P2860
P304
P356
10.1158/2326-6066.CIR-14-0206
P577
2015-06-03T00:00:00Z